Notice bibliographique
Résumé
Rethinking Parkinson's.ropinirole (as ropinirole hydrochloride) TabMs: 0.25 mg, 1.0 mg, 2.0 mg, 5.0 mg THERAPEUTIC CLASSIFICATION Antiparkinsonian Agent / Dopamine Agonist INDICATIONS AND CLINICAL USE REQUIP (ropinirole hydrochloride) is indicated in the treatment of the signs and symptoms of idiopathic Parkinson's disease.REQUIP can be used both as early therapy, without concomitant levodopa and as an adjunct to levodopa.CONTRAINDICATIONS REQUIP (ropinirole hydrochloride) is contraindicated in patients with a known hypersensitivity to ropinirole hydrochloride or the excipients of the drug product.WARNINGS Orthostatic Symptoms -Dopamine agonists appear to impair the systemic regulation of blood pressure with resulting orthostatic symptoms of dizziness or lightheadedness, with or without documented hypotension.These symptoms appear to occur especially during dose escalation.Therefore, patients treated with dopamine agonists should be carefully monitored for signs and symptoms of orthostatic hypotension, especially during dose escalation and should be informed of this risk.Hallucinations -In controlled trials, REQUIP (ropinirole hydrochloride) caused hallucination in 5.1% of patients during early therapy (1.4% in the placebo group) and in 10.1% of patients receiving REQUIP and levodopa (4.2% receiving placebo and levodopa).Hallucination was of sufficient severity that It led to discontinuation in 1.3% and 1.9% of patients during early and adjunct therapy, respectively.The incidence of hallucination was dose-dependent both in early and adjunct therapy studies.PRECAUTIONS Cardiovascular -Since REQUIP (ropinirole hydrochloride) has not been studied in patients with a history or evidence of significant cardiovascular disease including myocardial infarction, unstable angina, cardiac decompensation, cardiac arrhythmias, vaso-occlusive disease (including cerebral) or cardiomyopathy, it should be used with caution in such patients.There is limited experience with REQUIP in patients treated with antihypertensive and antiarrhythmic agents.Consequently, in such patients, the dose of REQUIP should be titrated with caution.Neuroleptic ': Incidence ot adverse event <1 %.When REQUIP is administered as adjunct therapy to levodopa, the dose of levodopa may be decreased gradually as tolerated once a therapeutic effect with REQUIP has been observed.REQUIP should be discontinued gradually over a 7-day period.The frequency of administration should be reduced from three times daily to twice daily for 4 days.For the remaining 3 days, the frequency should be reduced to once dally prior to complete withdrawal of REQUIP.Renal and Hepatic Impairment: In patients with mild to moderate renal impairment, REQUIP may be titrated In the recommended manner according to clinical response.Patients with severe renal impairment or on hemodialysis have not been studied and administration of REQUIP to such patients is not recommended.Patients with hepatic impairment have not been studied and administration of REQUIP to such patients is not recommended.Estrogen Replacement Therapy: In patients already receiving estrogen replacement therapy, REQUIP may be titrated in the recommended manner according to clinical response.However, if estrogen replacement therapy is stopped or started during treatment with REQUIP, adjustment of the REQUIP dosage may be required.AVAILABILITY OF DOSAGE FORM REQUIP is supplied as a pentagonal film-coated Tlltab*tablet with beveled edges containing ropinirole (as ropinirole hydrochloride) as follows: 0.25 mg -white imprinted with SB and 4890; 1.0 mg -green imprinted with SB and 4892; 2.0 mg -pale pink Imprinted with SB and 4893; 5.0 mg -blue tablets imprinted with SB and 4894.REQUIP Is available In bottles in the pack size of 100 tablets.It Is also available in 0.25 mg as a single unit blister pack of 21 tablets.Full Product Monograph available to practitioners upon request.REFERENCES: 1. Rascol 0, ef a/.Ropinirole in the Treatment of Early Parkinson's Disease: A 6-Month Interim Report of a 5-Year Levodopa-controlled Study.Mov D/sortf 1998;13:39-45.4. Schrag AE, ef a/.The Safety of Ropinirole, a selective non-ergoline dopamine agonist in patients with Parkinson's disease.
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
Comment cette classification a été obtenuedéplier
Prédiction machine sur la base complète
Imitation des enseignantsNi prévalence calibrée, ni vérité terrain. Validation humaine à venir. Le volet Gemma est une étiquette directe du modèle pour chaque travail de la base, lue sur la notice réduite au titre. Le volet Codex est un classifieur appris des 10 348 étiquettes directes de Codex et calibré sur les taux pondérés de l'échantillon; les champs sans appui suffisant ne portent aucun appel Codex. Le mode candidate est l'union des deux volets; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont pas des étiquettes humaines.
Scores du classifieur distillé par catégorie (deux têtes)
| Catégorie | Codex | Gemma |
|---|---|---|
| Métarecherche | 0,001 | 0,008 |
| Méta-épidémiologie (sens strict) | 0,000 | 0,000 |
| Méta-épidémiologie (sens large) | 0,001 | 0,000 |
| Bibliométrie | 0,001 | 0,001 |
| Études des sciences et des technologies | 0,001 | 0,001 |
| Communication savante | 0,002 | 0,001 |
| Science ouverte | 0,001 | 0,001 |
| Intégrité de la recherche | 0,003 | 0,002 |
| Charge utile insuffisante (le modèle a refusé de juger) | 0,207 | 0,093 |
Scores machine (provisoires)
Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.
Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.
score_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découleClassification
machine, non validéePrédiction automatique; un appel candidat d’une seule source (Gemma direct ou Codex distillé), pas un consensus.
Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».